Switch View
© PR Newswire
08.09.2025
ISIN: US83444M1018
Solventum Corporation
SOLV
LISTED
NYSE
Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
News Preview
ST. PAUL, Minn., Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of u...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: US04962H2094
Atossa Therapeutics, Inc.
ATOS
LISTED
NASDAQ
Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
News Preview
Type C FDA Meeting Requested, Update Expected by Year-End 2025
SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating development of low-dose...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: US00444T2096
Talphera Inc
TLPH
LISTED
NASDAQ
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
News Preview
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors
$17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the prim...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
08.09.2025
ISIN: US68236V3024
ETHZilla Corporation
ETHZ
LISTED
NASDAQ
ETHZilla Announces ETH Accumulation and Leadership Updates
News Preview
Company has accumulated 102,246 ETH at an average acquisition price of $3,948.72, valued at approximately $443 million
McAndrew Rudisill appointed as Chief Executive Officer, will continue to serve as Chairman
Provides update on previously announced stock repurchase program
PALM BEACH, Fla., Sept. 8, 2025 /PRNewswire/ -- ETHZilla Corporation (Nas...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
08.09.2025
ISIN: US09073N2018
BioSig Technologies, Inc.
BSGM
LISTED
NASDAQ
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
News Preview
Partnership unlocks exclusive tokenization rights, a four percent (4%) annual yield target on physical bullion, revenue share tied to leasing volumes and the creation of a groundbreaking institutionalized asset providing yield on physical gold holdings...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant’s FDA-approved Shield™ blood test. The partnership will bring Shield to mo...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US1598641074
Charles River Laboratories International Inc
CRL
LISTED
NYSE
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
News Preview
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and
Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT.
M...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US6047491013
Mirum Pharmaceuticals Inc
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US53566P1093
Lineage Cell Therapeutics Inc.
LCTX
LISTED
TLV
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufactu...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US74765K1051
Quantum-Si Inc
QSI
LISTED
NASDAQ
Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing
News Preview
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the launch of the V4 Sequencing Kit. The new kit is compatible with both the Platinum® and Platinum® Pro instruments.
The V4 Sequencing Kit improves sequencin...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: GG00BMF1JR16
Genius Sports Limited
GENI
LISTED
NYSE
Genius Sports Strikes Expanded Official Data, Trading and BetVision Partnership With Hard Rock Bet Sportsbook
News Preview
Genius Sports Limited (“Genius Sports”) (NYSE:GENI) has expanded its long-term partnership with Hard Rock Bet Sportsbook (“Hard Rock Bet”) to power the top-rated platform with its market-leading official data, trading and marketing solutions, as well as its ground-breaking BetVision product.
Genius Sports has worked in partnership with the leadi...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025
News Preview
White Bear Lake, Minnesota--(Newsfile Corp. - September 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present virtually at the H.C. Wain...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
08.09.2025
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year
News Preview
SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has received the Gold Medal by EcoVadis sustainability rating for the second consecutive year. This achievement reflec...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US88165K1016
Tevogen Bio Holdings Inc.
TVGN
LISTED
NASDAQ
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
News Preview
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-4...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US74019P1084
Precision BioSciences Inc
DTIL
LISTED
NASDAQ
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
News Preview
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled “Optimi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US74587B1017
Pulse Biosciences Inc
PLSE
LISTED
NASDAQ
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowin...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US42238H1086
HeartBeam, Inc.
BEAT
LISTED
NASDAQ
HeartBeam’s Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias
News Preview
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced new study data demonstrating that there were no significant differences in the detection of atrial fibrillation, atrial flutter and sinus rhythm when HeartBeam’s deep learning algorithms wer...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
ISIN: CA74290V2049
Promino Nutritional Sciences Inc.
MUSL
LISTED
CSE
Promino Nutritional Sciences Inc. Announces Change of Director and Officer
News Preview
Burlington, Ontario--(Newsfile Corp. - September 8, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the "Company" or "Promino") is pleased to announce that Moira Ong has been appointed as Chief Financial Officer and Corporate Secretary and Vito Sanzone has been appointed as a Director of the Company.Mr. Sanzone i...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
ISIN: CA12675Q1019
C21 Investments Inc.
CXXI
LISTED
CSE
C21 Investments Announces Completion of Non-Dilutive Creation and Issuance of Subordinate Voting Shares
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) ("C21" or the "Company"), a vertically integrated cannabis company, today announced the completion of a transaction (the "Transaction") pursuant to which the Company has amended its authorized share structure and Articles to create a...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
ISIN: CA68405H1001
Optimi Health Corp
OPTI
LISTED
CSE
Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") rel...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US03152W1099
Amicus Therapeutics Inc
FOLD
LISTED
NASDAQ
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
News Preview
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US58468P2065
MediciNova Inc
MNOV
LISTED
NASDAQ
MediciNova Provides Shareholder Update on Key Developments
News Preview
LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US31447E1055
Femasys Inc
FEMY
LISTED
NASDAQ
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
News Preview
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: US04216R1023
Armata Pharmaceuticals, Inc.
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
News Preview
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02
LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specifi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and olde...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US24906P1093
DENTSPLY SIRONA Inc
XRAY
LISTED
NASDAQ
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives
News Preview
Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US1711262048
Pelthos Therapeutics Inc.
PTHS
LISTED
XASE
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
News Preview
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming S...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
News Preview
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US21900C3088
CorMedix Inc
CRMD
LISTED
NASDAQ
CorMedix Announces Strategic Minority Investment in Talphera
News Preview
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq:...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US44975P1030
I-Mab
IMAB
LISTED
NASDAQ
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
News Preview
ROCKVILLE, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2 (CLDN18.2)-direct...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: US28414H1032
Elanco Animal Health Inc
ELAN
LISTED
NYSE
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
News Preview
Credelio Quattro marked $100 million in net sales making it Elanco's fastest pet health blockbuster in history and one of the industry's fastest ever, especially with a single geographic approvalCredelio Quattro joins Experior® as Elanco's second of six recently launched blockbuster-potential products to reach the $100 million annual net sales mi...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US6294441000
NRx Pharmaceuticals, Inc.
NRXP
LISTED
NASDAQ
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
News Preview
MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Dura Medical (Dura). Dura, togethe...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group Appoints Vice President of Finance
News Preview
Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased to announce with continued franchising demand and steady organic growth, we have brought on a Vice President of Finance to oversee these growth ve...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US4158581094
Harrow Inc
HROW
LISTED
NASDAQ
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
News Preview
Announces Commitment for New $40 Million Revolving Credit Facility...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US92243A2006
Vaxart Inc
VXRT
LISTED
NASDAQ
Vaxart Announces Adjournment of Special Meeting of Stockholders
News Preview
Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: AU000000IMM6
Immutep Ltd
IMM
LISTED
ASX
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
News Preview
SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the Connective...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
News Preview
Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in the neoadjuvant setting of primary uveal melanomaManageable safety profile with mostly Grade 1 and 2 treatment-related adverse eventsPhase 3 registrat...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US02155X2053
Alterity Therapeutics Limited
ATHE
LISTED
NASDAQ
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
News Preview
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: AU000000OCC6
Orthocell Limited
OCC
LISTED
ASX
Remplir™ Study Delivers Compelling 81% Success Rate
News Preview
Data to support US sales roll out and EU + UK regulatory submissions
Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. Real World Evidence (RWE) patient data collected in the study confirms Orthocell's nerve repair product, Remplir, as the ideal medical...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US88322Q1085
TG Therapeutics Inc
TGTX
LISTED
NASDAQ
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
News Preview
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: CA74373X1015
PharmaCorp RX Inc.
PCRX
LISTED
TSX
PharmaCorp to Acquire a Pharmacy in Ontario for $5,300,000, New Non-Binding Letter of Intent to Acquire Two Pharmacies in Eastern Canada, Updates on Previously Announced Non-Binding Letters of Intent and Filing of Q2 Investor Presentation
News Preview
PHARMACORP TO ACQUIRE PHARMACY FOR $5.3MM, NON-BINDING LOI TO ACQUIRE 2 PHARMACIES IN EASTERN CANADA, UPDATES ON PREVIOUS LOIs, FILING OF Q2 PRESENTATION...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US70261F1030
Pasithea Therapeutics Corp.
KTTA
LISTED
NASDAQ
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
News Preview
Pasithea Tx (Nasdaq: KTTA) advances PAS-004 NF1 trial to Cohort 2 (8mg) after SRC confirms safety; interim data from first two cohorts expected Q1 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
News Preview
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US00848H1086
AgeX Therapeutics, Inc.
AGE
LISTED
XASE
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conferen...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: US75383L1026
Rapport Therapeutics Inc.
RAPP
LISTED
NASDAQ
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
News Preview
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: KYG4212K1040
Gushengtang Holdings Limited
2273
LISTED
HKSE
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
News Preview
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: KYG4212K1040
Gushengtang Holdings Limited
2273
LISTED
HKSE
Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion
News Preview
GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue of RMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year-on-year to RMB 150 million. The expansion in net...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: IE00B56GVS15
Alkermes Plc
ALKS
LISTED
NASDAQ
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
News Preview
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses –
– Alixorexton Was Generally Well Tolerated at All Doses Tested –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Sept. 8...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: IE00B56GVS15
Alkermes Plc
ALKS
LISTED
NASDAQ
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
News Preview
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses –
– Alixorexton Was Generally Well Tolerated at All Doses Tested –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Sept....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) Slashes Outstanding Share Count by 680,000,000 Shares
News Preview
MESA, ARIZONA / ACCESS Newswire / September 8, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) (the "Company" or "MDCE") today announced that Chief Executive Officer Marshall Perkins has voluntarily surrendered 680,000,000 shares of common stock back to the Company's treasury. This action reduces the total number of outsta...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: US8740602052
Takeda Pharmaceutical Company
TAK
LISTED
NYSE
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
News Preview
Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
ISIN: US14757U2087
CASI Pharmaceuticals, Inc.
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
News Preview
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports continued development- No serious adverse events or dose-limiting toxicities have been reported SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:C...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
ISIN: US29350E1047
Enochian Biosciences, Inc
ENOB
LISTED
NASDAQ
Lunai Bioworks Strengthens European Strategy Through Restructuring
News Preview
Company remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug discovery and biodefense company, today reaffirmed its long-term commitment to European markets and partnerships while announcing the elimination of it...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
News Preview
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentiall...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
ISIN: CH0432492467
Alcon AG
ALC
LISTED
NYSE
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
News Preview
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will present compelling scientific data at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen, Denmark from 12-15 September. During the meeting, Alcon will showcase groundbreaking cataract, refractive a...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Starkes Wachstum bei Umsatz und Konzernergebnis im ersten Halbjahr 2025
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR
Fribourg, 8. September 2025
AEVIS VICTORIA SA (AEVS.SW) – Starkes Wachstum bei Umsatz und Konzernergebnis im ersten Halbjahr 2025
AEVIS VICTORIA SA (AEVIS) erzielte per 30. Juni 2025 einen konsolidierten Bruttoumsatz von CHF 621.3 Millionen (1H2024: CHF 527.6 Mio.), was einem Anstieg von 17.7% gegenüber 2024 ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.09.2025
ISIN: CH0478634105
Aevis Victoria SA
AEVS
LISTED
SIX
AEVIS VICTORIA SA – Strong growth in revenue and consolidated results in the first half of 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Fribourg, 8 September 2025
AEVIS VICTORIA SA (AEVS.SW) – Strong growth in revenue and consolidated results in the first half of 2025
AEVIS VICTORIA SA (AEVIS) reported a consolidated gross revenue of CHF 621.3 million as at 30 June 2025 (HY2024: CHF 527.6m), up 17.7% compared to 2024. Consolidated net......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.09.2025
ISIN: CH0468525222
Medacta Group SA
MOVE
LISTED
SIX
Medacta Group SA reports surge in adjusted EBITDA margin to 29.6% in constant currency in H1 2025
News Preview
Media Release – Ad-hoc announcement pursuant to Art. 53 LR
Medacta Group SA reports surge in adjusted EBITDA margin to 29.6% in constant currency1 in H1 2025
H1 2025 revenue accelerated to Euro 344.1 million, up 19.8% in c.c.1 or 19.2% in Euro
Adjusted EBITDA margin advanced to 29.6% in c.c. 1 up 270 bps yoy
Adjus......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
ISIN: US59564R8079
Biodexa Pharmaceuticals plc
BDRX
LISTED
NASDAQ
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
News Preview
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a late clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medic...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: JP3160400002
Eisai Co Ltd
45230
LISTED
XJPX
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
News Preview
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1
TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have bee...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
